To the Editor: In the February 1, 2006 issue of Clinical Cancer Research, Gréen et al. (1) described an association between G2677A/T single nucleotide polymorphism of MDR-1 gene and response to paclitaxel chemotherapy. The investigators state that ''the probability of responding to paclitaxel treatment is higher in homozygously mutated patients (TT or TA)''.
In our opinion, there are some issues to be discussed. The group of ''poor responders'' encompasses the whole spectrum of patients: from those with complete remission and diseasefree survival up to 12 months, to patients with progressive disease. Such a grouping is unconventional and the question arises whether an association with tumor response (according to guidelines of the WHO) has been studied. Taking into consideration the influence of Pgp polymorphism on paclitaxel pharmacokinetics, patients with complete remission and 1 year disease-free survival might be completely different from those who had progressive disease. In addition, the investigators presented a univariate analysis (by Fisher's test). As they pointed out, the group of ''good responders'' included more patients with low stage disease and with complete debulking. It should also be noticed that it included more well and moderately differentiated tumors. The associations presented are at the border of significance (P value from 0.03 to <0.05), and they would probably disappear if the Bonferroni correction for multiple analyses was taken into account.
We have determined the distribution of G2677A/T single nucleotide polymorphisms in a group of 86 Polish ovarian cancer patients with Federation Internationale des Gynaecologistes et Obstetristes stage IIB to IV disease, and with poor tumor differentiation. The patients were uniformly treated with taxol plus cisplatin or carboplatin for six cycles. Response to chemotherapy was evaluated according to the WHO criteria (2) . In addition, according to the criteria of platinum sensitivity (3), we identified a group of patients sensitive to treatment (complete remission with disease-free survival z180 days).
Four genetic variants were identified, i.e., GG (32.56%), GT (43.02%), TT (23.26%), GA (1.16%). We have not found any associations between TT genotype and response to treatment in univariate (m 2 test) and multivariate analyses (logistic regression model). Analysis of overall survival with Cox's proportional hazards models revealed a 2.5 times higher risk of death for patients with TT versus other genotypes (P = 0.01). This result might suggest that TT genotype in the MDR1 gene may enhance Pgp efficiency, or it might have occurred by chance. Analyses on relatively small clinical groups may easily generate artifacts. The potential association between G2677A/T missense single nucleotide polymorphisms and response to paclitaxelbased chemotherapy is still elusive. 
